Predictive value of HER-2 and Topoisomerase IIα in response to primary doxorubicin in breast cancer

This publication has 28 references indexed in Scilit:

• Retrospective Analysis of Topoisomerase IIa Amplifications and Deletions As Predictive Markers in Primary Breast Cancer Patients Randomly Assigned to Cyclophosphamide, Methotrexate, and Fluorouracil or Cyclophosphamide, Epirubicin, and Fluorouracil: Danish Breast Cancer Cooperative Group
  Journal of Clinical Oncology, 2005
• Chromogenic In Situ Hybridization for the Detection of HER-2/neuGene Amplification in Breast Cancer With an Emphasis on Tumors With Borderline and Low-Level Amplification
  American Journal of Clinical Pathology, 2005
• Correlation between HER‐2 expression and response to neoadjuvant chemotherapy with 5‐fluorouracil, doxorubicin, and cyclophosphamide in patients with breast carcinoma
  Cancer, 2003
• Topoisomerase II-α (topoII) and HER2 amplification in breast cancers and response to preoperative doxorubicin chemotherapy
  European Journal Of Cancer, 2003
• Assessment of histologic features and expression of biomarkers in predicting pathologic response to anthracycline-based neoadjuvant chemotherapy in patients with breast carcinoma
  Cancer, 2002
• Prognostic significance of a complete pathological response after induction chemotherapy in operable breast cancer
  British Journal of Cancer, 2002
• Topoisomerase IIα Expression in Breast Cancer: Correlation with Outcome Variables
  Laboratory Investigation, 2000
• ERBB2 overexpression in breast carcinomas: no positive correlation with complete pathological response to preoperative high-dose anthracycline-based chemotherapy
  European Journal Of Cancer, 2000
• pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long‐term follow‐up
  Histopathology, 1991
• Human Breast Cancer: Correlation of Relapse and Survival with Amplification of the HER-2/ neu Oncogene
  Science, 1987